Description |
Oglufanide disodium is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis C viral infection.
Oglufanide disodium was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by Implicit Bioscience in 2005.
Oglufanide disodium works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.
|
